Industry Outlook
The joint pain injections market is set to reach from US$ 2,146.0 Mn in 2017 to US$ 4,888.5 Mn by 2026 exhibiting outstanding growth at a compound annual growth rate (CAGR) of 9.7% during the forecast period from 2018 to 2026. As per the latest research citing brought forward by Global Burden of Disease Study the burden associated with musculoskeletal disorders is approximately 6.8% of DALYs worldwide.
Market Synopsis
Get a sample copy for more information
"Excellent lubrication and shock absorbing properties similar to synovial fluid has led to the increasing demand for hyaluronic acid injections for joint pains"
Hyaluronic acid injection is reigning the injections segment for joint pain injections market. The human joints are similar to gears subjected to constant wear and tear, hyaluronic acid possess excellent lubrication and shock absorbing properties similar to synovial fluid thereby reducing joint stiffness and tenderness. Corticosteroid injections are used as an adjuvant medication in joint pain owing to its anti-inflammatory properties and ability to provide short term relief in joint sprains experienced by athletes and industrial workers.
Get a sample copy for more information
"Significant rise in tenosynovitis and prolonged physical activity drive the knee & ankle joint market growth"
Currently knee & ankle joints are dominating the joint segment for joint pain injections market. The major factors associated with its market growth are significant rise in tenosynovitis and prolonged physical activity. Increasing competition among athletes and rampant growth of production and manufacturing segment further bolster the knee & ankle joints market growth. Shoulder & elbow joints are anticipated to register impressive growth in the near future owing to increasing utilization of electronic gadgets such as laptops, personal computer and mobile phones among general population. Rising prevalence of rotator cuff injury further consolidate the shoulder & elbow joints market growth.
Get a sample copy for more information
"Rising prevalence of obesity and high acceptance of viscosupplementation drive the market growth in North America"
North America with a share of 34% is leading the regional segment for joint pain injections market. The chief attributes responsible for its dominance are rising prevalence of obesity and high acceptance of viscosupplementation. Domicile of key players such as Sanofi S.A., Allergan, Plc., Pfizer, Inc. etc. provide necessary impetus to the joint pain injections market growth in North America region. Europe is in the second position with a share of 28% owing to the rising prevalence of osteoarthritis in geriatric population. Affordable reimbursement scenario associated with joint pain injections propel the market growth in European region. Asia Pacific holds 20% market share and will grow at a faster pace during the forecast period on account of significant rise in musculoskeletal disorders and increasing cases of accidents and physical trauma.
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market segmentation comprises of by injection, joint and geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Billion |
| Segmentation |
By Injection (2016–2026; US$ Mn)
• Hyaluronic Acid Injection
• Corticosteroid Injection
• Others
|
|
By Joint (2016–2026; US$ Mn)
• Hip Joint
• Knee & Ankle
• Shoulder & Elbow
• Facet Joints of the Spine
• Others
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
Pharmaceutical companies pioneering in the joint pain injections market are Allergan, Plc., Anika Therapeutics, Inc., Bioventus LLC., Chugai Pharmaceutical Co., Ltd., Flexion Therapeutics, Inc., Ferring B.V., Pfizer, Inc., Sanofi S.A., SEIKAGAKU Corporation and Zimmer Biomet Holdings, Inc.
Key questions answered in this report
- Which pharmaceutical companies are manufacturing joint pain injections?
- What are the latest market trends prevalent in the joint pain injections market?
- What are the different causes associated with joint pain?
- What will be the market performance of shoulder & elbow joints?
- What is the importance of hyaluronic acid in attenuating excruciating pain associated with joint osteoarthritis?
- Which parameters are accounted for the dominance of North America?
